Melanotan II and Melanoma What the Research Actually Shows Melanotan II is a synthetic version of a natural hormone linked to skin pigmentation. Most people know it for tanning, but research has looked at how it interacts with melanoma cells This study did not show MTII directly killing cancer cells. What it showed was a shift in how aggressive those cells behave MTII reduced the ability of melanoma cells to move, invade nearby tissue, and form new colonies. That matters because spread is what makes melanoma dangerous In animal models, tumor progression slowed down. The tumors did not grow as aggressively, and overall development was reduced It also increased apoptosis. That means more cancer cells were pushed toward programmed cell death instead of continuing to survive Another key effect was reduced blood vessel formation around tumors. Cancer relies on blood supply to grow, so limiting that slows things down Mechanistically, MTII activates the MC1R receptor. This increases PTEN, which is a tumor suppressor. When PTEN goes up, it shuts down pathways like AKT and NFkB that cancer uses to survive and spread It also lowered COX 2 and PGE2, which are tied to inflammation and tumor growth The takeaway is not that MTII cures melanoma. It is that it may reduce how aggressive melanoma behaves under certain conditions

We've made a decision that the last 2 peptira kit giveaways will be skool exclusive . This increases your chances dramatically to win!

It's only fair I address the situation head-on. As of now, I've found no direct evidence of Ion products coming up short in testing. There was what I was told a mishap with COAs being published while the product was never released. Ion was a strong company when I took them on in the beginning. If nothing else, they've become passive, and I do not recommend products that they may carry that will not be effective, such as shampoos amd strip things of that nature. I will do my due diligence and investigate the company; that's my job. And I will inform you guys as I find out new information.

How many have heard of this... gonna do a break down and look ahead on this one today.

Brenipatide is a new incretin-based peptide in development by Eli Lilly and Company. It works on the same general pathways as tirzepatide and retatrutide, targeting GIP and GLP-1 receptors. That part isn’t exciting. What’s different is what they’re trying to use it for. This isn’t just being looked at for fat loss or blood sugar. It’s being studied for things like alcohol cravings, smoking relapse, and even opioid-related behavior. That should tell you right away this isn’t just about eating less. This is about how the brain handles reward. Most people think GLP-1 equals appetite suppression. That’s surface level. The deeper layer is that these pathways interact with dopamine and reward signaling. That’s why some people on these compounds lose interest in food, alcohol, even certain habits. Brenipatide is being pushed further into that lane. So instead of thinking “this helps you eat less,” think “this might help you want less.” That’s a completely different conversation. Now here’s the reality. This is still in research. No real protocols, no long-term outcome data, and no clear idea yet where it will land compared to something like tirzepatide or retatrutide. So this isn’t something you should be chasing. But it is something to watch. Because if it does what they’re hoping, this class of peptides stops being just about fat loss and starts becoming about controlling cravings, habits, and behaviors at a much deeper level. That’s where things get interesting.